{
  "id": 6219731,
  "title": "Emyria FY 2026 slides: revenue triples as clinic network expands",
  "url": "https://urgent.news/2026/09/08/emyria-fy-2026-slides-revenue-triples-as-clinic-network-expands",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-08T02:28:07.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/emyria-fy-2026-slides-revenue-triples-as-clinic-network-expands-93CH-4890769"
  },
  "original_language": "en",
  "account": "Emyria Limited (ASX:EMD) reported its FY 2026 results on September 8, highlighting a 191% revenue increase to AUD 4.05 million and showcasing its rapid expansion of the Australian psychedelic-therapy clinic network. The company's share price fell by 2.17% to $0.05, indicating investor skepticism about achieving profitability at the group level. Australia is the first country to legalize psychedelic-assisted therapy using MDMA for PTSD and psilocybin for treatment-resistant depression, granting Emyria a first-mover advantage in this burgeoning industry. By the end of FY 2026, Emyria had expanded from one clinic to five, with capacity growing from 4 to 18 beds, treating 138 patients, an astounding 475% increase from the 24 patients treated in FY 2025. The Perth clinic achieved break-even and profitability, validating the business model's unit economics. Emyria's treatment model combines intensive psychotherapy with psychedelic-assisted therapy across a structured patient journey, with annualized revenue potential of AUD 46.8 million at full utilization. The Australian market offers a substantial opportunity, with approximately 1.1 million adults suffering from major depression and 1.5 million with PTSD. Emyria's growth strategy includes securing diverse reimbursement pathways, such as Medibank's national funding agreement and Department of Veterans' Affairs approval for veteran mental health treatment. Competitive advantages stem from Australia's pioneering regulatory framework for psychedelic therapy, allowing Emyria to build infrastructure and relationships while other countries lag behind.",
  "summary": null,
  "key_points": [
    "Emyria's FY 2026 revenue triples to AUD 4.05 million",
    "Clinic network expands from 1 to 5 clinics, capacity grows from 4 to 18 beds",
    "Perth clinic achieves break-even and profitability"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}